

# Nicotine Gum for Pregnant Smokers

## A Randomized Controlled Trial

Cheryl Oncken, MD, MPH, Ellen Dornelas, PhD, John Greene, MD, Heather Sankey, MD, Allen Glasmann, MD, Richard Feinn, PhD, and Henry R. Kranzler, MD

**OBJECTIVE:** To estimate the safety and efficacy of treatment with 2-mg nicotine gum for smoking cessation during pregnancy.

**METHODS:** Pregnant women who smoked daily received individualized behavioral counseling and random assignment to a 6-week treatment with 2-mg nicotine gum or placebo followed by a 6-week taper period. Women who did not quit smoking were instructed to reduce the number of cigarettes smoked by substituting with gum. Measures of tobacco exposure were obtained throughout the study.

**RESULTS:** Participants in the nicotine (n=100) and placebo (n=94) groups were comparable in age, race/

ethnicity, and smoking history. Biochemically validated smoking-cessation rates were not significantly higher with nicotine gum compared with placebo (after 6 weeks of treatment: 13% compared with 9.6%,  $P=.45$ ; at 32–34 weeks of gestation: 18% compared with 14.9%,  $P=.56$ ). Using a completer analysis, nicotine gum significantly reduced the number of cigarettes smoked per day (nicotine gum:  $-5.7$  [standard deviation (SD)=6.0]; placebo:  $-3.5$  [SD=5.7],  $P=.035$ ), and cotinine concentration (nicotine gum:  $-249$  ng/mL [SD=397]; placebo:  $-112$  ng/mL [SD=333];  $P=.04$ ). Birth weights were significantly greater with nicotine gum compared with placebo (3,287 g [SD=566] and 2,950 g [SD=653], respectively,  $P<.001$ ). Gestational age was also greater with nicotine-replacement therapy than with placebo (38.9 weeks [SD=1.7] and 38.0 weeks [SD=3.3], respectively;  $P=.014$ ).

**CONCLUSION:** Although nicotine gum did not increase quit rates, use of nicotine gum increased birth weight and gestational age, two key parameters in predicting neonatal wellbeing.

**CLINICAL TRIAL REGISTRATION:** Clinicaltrials.gov, www.clinicaltrials.gov, NCT00115687

(*Obstet Gynecol* 2008;112:859–67)

**LEVEL OF EVIDENCE:** I

From the Departments of Medicine and Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, Connecticut; the Division of Preventive Cardiology and the Department of Obstetrics and Gynecology, Hartford Hospital, Hartford, Connecticut; the Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts, and the Hospital of Central Connecticut, Southington, Connecticut; and the Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, and University of Connecticut School of Medicine, Farmington, Connecticut.

Supported by National Institutes of Health grants R01 DA15167, K24 AA13736, M01 RR006192, P50 DA013334, P50 AA015632. Nicotine gum was provided free of charge from Glaxo-Smith Kline (Philadelphia, PA). Presented in part at the Annual Meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico, June 14–19, 2008.

Corresponding author: Cheryl Oncken, MD, MPH, (MC 3940), University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3940; e-mail: oncken@nso2.uchc.edu.

### Financial Disclosure:

Dr. Oncken has received consulting fees and honoraria from Pfizer (New York, NY) for advisory board meetings. She has received at no cost nicotine and/or placebo products from Glaxo-SmithKline (Philadelphia, PA) for smoking-cessation studies (ie, for pregnant women, postmenopausal women). She has received grant funding from Pfizer and from Nabi Biopharmaceuticals (Boca Raton, FL). Dr. Kranzler has received consulting fees from Ortho-McNeil Pharmaceuticals (Raritan, NJ), H. Lundbeck A/S (Copenhagen, Denmark), Forest Pharmaceuticals (St. Louis, MO), elbion NV (Leuven, Belgium), Sanofi-Aventis (Bridgewater, NJ), Solvay Pharmaceuticals (Brussels, Belgium), and Alkermes, Inc. (Cambridge, MA). He has received research support from Ortho-McNeil Pharmaceuticals and Bristol-Myers Squibb Company (New York, NY), and honoraria from Forest Pharmaceuticals and Alkermes, Inc. The other authors have no potential conflicts of interest to disclose.

© 2008 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins.

ISSN: 0029-7844/08

Tobacco smoke contains more than 3,500 chemicals, including 100 carcinogens and mutagens, carbon monoxide, nicotine, and hydrogen cyanide, all of which can be very harmful to fetal development.<sup>1</sup> Smoking doubles the risk of delivering a low birth weight (less than 2,500 g) or premature (less than 37 weeks of gestation) neonate and increases the risk of numerous adverse perinatal and neonatal outcomes.<sup>2,3</sup> Very low birth weight newborns (less than 1,500 g) in particular have exponential increases in morbidity and mortality compared with newborns of normal weight.<sup>4</sup> Smoking by pregnant women has been blamed for up to 12% of perinatal deaths and 10% of neonatal deaths in the United States.<sup>3</sup>



Approximately 12% of U.S. women smoke during pregnancy,<sup>2</sup> and smoking is most prevalent among women who are socioeconomically disadvantaged.<sup>5</sup> The majority of pregnant women who smoke before becoming pregnant continue to smoke during pregnancy,<sup>6</sup> with behavioral interventions alone yielding quit rates that rarely exceed 18%.<sup>7</sup>

Given these circumstances, a need exists to examine the safety and efficacy of pharmacotherapy for smoking cessation during pregnancy. Nicotine-replacement therapies approximately double quit rates relative to placebo in studies in nonpregnant individuals.<sup>7</sup> However, there are conflicting findings as to whether nicotine-replacement therapy is a safe and effective adjunctive treatment for smoking cessation during pregnancy.<sup>8,9</sup>

We conducted a prospective, randomized, double blind, placebo-controlled clinical trial of the safety and efficacy of 2-mg nicotine gum in pregnant smokers. We chose this nicotine formulation because our previous work suggested that 2-mg nicotine gum reduced nicotine exposure and generally had a lesser effect on maternal and fetal hemodynamics than ad libitum smoking.<sup>10</sup> Moreover, based on evidence from the general population showing that different nicotine-replacement therapy formulations are similar in efficacy but that an intermittent form (eg, gum) may deliver a lower dose of nicotine than a continuous form (eg, patch),<sup>7</sup> the intermittent form is recommended for smoking cessation during pregnancy. The primary outcome for this study was biochemically confirmed 7-day point prevalence abstinence rates at two time points: after 6 weeks of gum use and at the end of pregnancy. Other major endpoints included the birth weight of the offspring and measures of smoking reduction.<sup>11</sup>

## MATERIALS AND METHODS

The study was approved by the Institutional Review Board at the University of Connecticut Health Center (Farmington, CT) and at each of the enrollment sites: Hartford Hospital (Hartford, CT), Hospital of Central Connecticut (New Britain, CT), and Baystate Medical Center (Springfield, MA). The study was conducted under an Independent New Drug Application by the U.S. Food and Drug Administration (IND #64,648) and was registered on Clinicaltrials.gov (NCT00115687). An independent Data and Safety and Monitoring Board reviewed ongoing trial data, including efficacy rates and serious adverse events, throughout the study. Participants were recruited from July 30, 2003, to September 25, 2006, with the last study participant completing participation on April 17, 2007. Partici-

pants were primarily recruited from prenatal clinics at Hartford Hospital, New Britain General Hospital, and Baystate Medical Center. Clinic personnel would identify smokers and inquire whether the patient was interested in a research study. If so, on site research personnel would meet with potential participants. We also accepted referrals from private practitioners.

The study protocol consisted of eight visits. At the screening visit, we obtained written consent, and assessed inclusion/exclusion criteria. At the next two visits (baseline and visit 1) women received individual smoking cessation counseling by a smoking cessation therapist. At the baseline visit and every visit thereafter, the study nurse dispensed study medication, assessed smoking cessation progress, encouraged cessation, and collected information on adverse events. The timing of study visits is outlined in Figure 1.


We obtained written informed consent from all participants before implementing any study procedures. The consent form was available in English and Spanish. We obtained parental consent and participant assent from minors enrolled at the two sites in Connecticut; however, in Massachusetts pregnant teens aged 16–18 years are emancipated, so that parental consent was not required.

Pregnant women were included if they were 1) currently smoking at least one cigarette per day, 2) at 26 weeks of gestation or less, 3) 16 years of age or older, 4) able to speak English or Spanish, 5) intending to carry the pregnancy to term, and 6) living in a stable residence. Exclusion criteria were 1) evidence of a current illicit drug or alcohol use disorder within the preceding month (women taking methadone maintenance were included if they reported not currently using illicit drugs), 2) twins or other multiple gestation, 3) an unstable psychiatric problem (eg, suicidal ideation), an unstable medical problem (eg, preeclampsia, threatened abortion), or a medical problem that would interfere with study participation (eg, temporo-mandibular joint problems). Women with high-risk pregnancies (eg, with diabetes or human immunodeficiency virus [HIV]) were included if they were medically stable.

A medical history and the Structured Clinical Interview for DSM-IV to assess major depression and posttraumatic stress disorder<sup>12</sup> were administered before treatment. Other assessments included a smoking history, the Fagerstrom Test for Nicotine Dependence,<sup>13</sup> selected questions from the Rhode Island Stress and Coping questionnaire,<sup>14</sup> and the 10-item Center for Epidemiologic Studies Depression Scale.<sup>15</sup>

The research pharmacy used a computerized urn randomization program to balance participant assign-





**Fig. 1.** Flow of participants through the study. \*Significantly different follow-up rates between nicotine and placebo groups (less than 0.05).

*Oncken. Nicotine Gum Use in Pregnant Smokers. Obstet Gynecol 2008.*

ment in the two treatment groups. The balancing variables were maternal age, gestational age at study entry, number of cigarettes smoked per day, health insurance (public or private), and use of methadone maintenance.<sup>16</sup>

Participants received two 35-minute counseling sessions (in English or Spanish) delivered by a research assistant trained to deliver smoking cessation counseling using a motivational interviewing approach,<sup>17,18</sup> which was previously shown to be effective when used in the same patient population.<sup>19</sup> Research assistants (including two native Spanish speakers) received 6 hours of didactic training, reviewed videotaped smoking cessation counseling sessions, and observed two counseling sessions delivered by the trainer. In addition to the counseling sessions, participants received printed educational materials that were tailored for use in pregnancy and twice-monthly telephone calls to monitor progress until delivery.

The counseling sessions were delivered at Baseline and Visit 1 and began with an assessment of

readiness to quit smoking based.<sup>20</sup> The initial counseling session 1) discussed the benefits of quitting smoking during pregnancy; 2) assessed the stage of change, 3) motivated the participant to quit and 4) had the participant set a quit date within the next week. Participants who did not commit to a quit date were instructed to reduce by half the number of cigarettes smoked per day during the first week and by another half during the second week, with the goal of achieving complete cigarette abstinence by the end of the third week of treatment. The second counseling session was scheduled within one week after the quit or reduction date, and focused on strategies to deal with smoking urges and withdrawal symptoms, with the goal of smoking cessation.

The study nurse dispensed study gum (nicotine 2-mg or placebo [Fertin Pharma, Vejle, Denmark]) at the baseline visit and at each subsequent visit. The placebo gum had a peppery taste to mimic the taste of nicotine gum. Gum was packaged in the same zipper foil packets to maintain the integrity of the blind.



Participants were instructed to chew one piece of gum for every cigarette they usually smoked per day, beginning on their quit date. However, participants were instructed to not chew more than 20 pieces per day. Participants who did not commit to a quit date were managed as above and were instructed to substitute one piece of nicotine gum daily for each cigarette that they eliminated.

Participants received 6 weeks of treatment with the gum followed by a 6-week taper period. Participants were encouraged to continue use of the gum as long as they were actively trying to quit smoking and were allowed to use study medication postpartum to prevent smoking relapse.

At every visit, study nurses monitored patients' smoking status (ie, cigarettes smoked/day, exhaled carbon monoxide [CO]) and adverse events. The following questionnaires were administered at every visit: Minnesota Withdrawal Symptom Checklist,<sup>21</sup> Rhode Island Stress and Coping Inventory,<sup>14</sup> and the Center for Epidemiologic Studies Depression Scale.<sup>15</sup>

The concentration of urinary cotinine, the major metabolite of nicotine and a measure of overall nicotine intake,<sup>11</sup> was obtained before treatment (at both screening and baseline visits) and at visits 2, 4, and 5. Urine samples obtained at screening, baseline and visit 2 (or the next available sample) were analyzed within 1 week to identify increased nicotine exposure due to gum use. Samples were analyzed by radioimmunoassay (with a detection level of 50 ng/mL). Participants were informed (by a research assistant not otherwise involved in patient contact) when the cotinine concentration while on treatment exceeded by 50% the higher of the screening or baseline cotinine measures, and they were instructed to reduce their smoking and/or gum use until the cotinine concentration returned to pretreatment values.

Urine for measurement of anabasine and anatabine concentrations was obtained at baseline and visits 4 and 5. Samples were analyzed by gas chromatography/mass spectrometry (with a detection level of 1 ng/mL). Anabasine and anatabine are minor tobacco alkaloids that are not altered by nicotine-replacement therapy.<sup>11</sup>

Information on adverse events, including serious adverse events was collected throughout the study. Study nurses also abstracted data on pregnancy and neonatal outcomes from the medical chart after delivery. A priori criteria for serious adverse events assessed by chart review included preterm (less than 37 weeks of gestation) delivery, low birth weight (less than 2,500 g), spontaneous abortion (unintended pregnancy loss at 20 weeks of gestation or less),

intrauterine fetal demise (fetal death in utero at more than 20 weeks of gestation but before delivery), newborn death (age 0–28 days), maternal hospitalization for a reason other than labor and delivery, and neonatal intensive care unit (NICU) admission.

We had planned to recruit 268 participants, which would have provided power in excess of 80% (with  $\alpha=.05$ , two-sided) to detect a doubling of quit rates (18% compared with 36%) and a 150-g difference in birth weight assuming a standard deviation (SD) of 425 g. However, after reviewing the efficacy data at the 6-week time point for 147 participants, the Data and Safety and Monitoring Board recommended that enrollment be stopped due to lack of efficacy. At the time of the interim analysis, the quit rate was approximately 14% in the nicotine gum group, and 7% in the placebo group and the Data and Safety and Monitoring Board reasoned that a much larger sample would be needed to detect a difference of this magnitude.

Analyses were performed using SPSS 15 (SPSS Inc., Chicago IL). Group means were compared using *t*-tests and frequencies were compared with the  $\chi^2$  test or Fisher exact test. The statistical significance for quit rates was adjusted from  $P<.05$  to  $P<.018$  to account for interim analyses. Nonnormally distributed variables were transformed as appropriate. The test for group differences at visits 4 and 5 was based on the change scores from baseline. For group differences at visits 4 and 5, two comparisons were made, one for completers (ie, women who provided data at these follow-up points), and one using the last observation carried forward method.

## RESULTS

As shown in Figure 1, 250 women gave written consent for study participation and 194 women were randomly assigned to treatment (128 women recruited from Hartford Hospital, 35 women from Baystate Medical Center, and 31 from New Britain General Hospital), with 100 women allocated to receive nicotine gum and 94 women allocated to the placebo control group. The groups were comparable on all demographic, smoking history, treatment history, and pregnancy history variables (Table 1). The mean age of participants was 25.1 year (SD=5.8). The majority of the sample was Hispanic, one-half did not complete high school, only 30% were married or cohabiting, and approximately one-third were currently working.

Participants smoked an average of 18 cigarettes/day before pregnancy and approximately 10 cigarettes/day during the week before study enrollment. The mean Fagerstrom Test for Nicotine Dependence



**Table 1. Baseline Characteristics**

	Placebo (n=94)	Nicotine (n=100)	P*
Age, y	24.7 (5.4)	25.5 (6.8)	.31
Race/ethnicity			.32
Hispanic	52 (55%)	53 (53%)	
Non-Hispanic white	30 (32%)	38 (38%)	
Non-Hispanic African American	7 (7%)	8 (8%)	
Other	5 (5%)	1 (1%)	
Education			.26
Less than high school	44 (47%)	53 (53%)	
High school	36 (39%)	28 (28%)	
More than high school	13 (14%)	19 (19%)	
% Married or partnered	28 (30%)	30 (30%)	.91
Insurance			.45
Public	80 (85%)	81 (81%)	
Private	14 (15%)	19 (19%)	
Methadone maintenance	6 (7%)	6 (6%)	.57
Antidepressant use	8 (9%)	6 (6%)	.51
Treatment history			
Mental health	38 (41%)	42 (42%)	.87
Substance abuse	19 (20%)	17 (17%)	.57
Smoking			
Number of cigarettes/d before pregnancy	17.8 (9.3)	17.5 (9.6)	.83
Number of cigarettes/d previous 7 days	8.7 (5.7)	10.2 (6.6)	.10
Number of previous quit attempts	2.55 (5.66)	3.03 (5.69)	.34
Fagerstrom score	3.55 (1.95)	3.83 (1.91)	.31
Pregnancy			
Number of pregnancies	3 (2, 4)	3 (2, 4)	.96
Gestational age at entry, wk	17.1 (5.5)	17.1 (5.6)	.92
History preterm delivery	16 (17%)	13 (13%)	.41
First pregnancy	16 (17%)	16 (16%)	.80


Continuous variables reported as mean (standard deviation). Ordinal variables are reported as median (interquartile range [25th, 75th percentile]).

\* $\chi^2$  for frequencies, *t*-test for means, Mann-Whitney *U* test for ordinal variables.

score was less than 4, indicating mild-to-moderate severity of nicotine dependence.<sup>13</sup> This was the first pregnancy for more than 15% of the women. Approximately 15% had a history of preterm delivery. Participants entered the study at a mean gestational age of 17.1 (SD=5.6) weeks.

After the baseline visit, overall, the nicotine group was more likely to attend study visits than the placebo group (71% compared with 60%;  $t_{(10)}=3.67$ ,  $P=.004$ ). The nicotine group participated at a significantly higher rate at visits 3 ( $\chi^2_{(1)}=5.26$ ,  $P=.022$ ) and 5 ( $\chi^2_{(1)}=4.74$ ,  $P=.029$ ) and at the postpartum visit ( $\chi^2_{(1)}=4.47$ ,  $P=.035$ ).

There were no statistically significant differences among the three sites for any of the smoking outcomes or for any of the birth outcomes. Also, there were no significant interactions between center and



**Fig. 2.** Seven-day point prevalence cigarette abstinence rates using an intent-to-treat analysis (n=194). Values are mean ( $\pm$ standard error). Abstinence was confirmed by an exhaled CO of less than 8 ppm.

Oncken. Nicotine Gum Use in Pregnant Smokers. *Obstet Gynecol* 2008.

treatment for any of the smoking outcomes. The intraclass correlation coefficient, which measures the homogeneity of the outcome variable within clusters (centers), was small for most outcomes (less than 5%) suggesting that center was not an important factor for the outcomes.

Figure 2 shows that biochemically-validated (exhaled CO value of less than 8 ppm), 7-day point prevalence smoking-cessation rates were nonsignificantly higher with nicotine-replacement therapy than placebo (after 6 weeks of treatment: 13% compared with 9.6%,  $P=.45$ ; at 32–34 weeks of gestation: 18% compared with 14.9%,  $P=.56$ ). Participants who did not attend the visit were treated as smokers. Table 2 displays measures of tobacco exposure by treatment group for baseline and study visits 4 and 5. Across both groups there was a significant decrease from baseline to visits 4 and 5 in the number of cigarettes smoked daily ( $t_{(125)}=11.03$ ,  $P<.001$  and  $t_{(135)}=9.26$ ,  $P<.001$ , respectively), exhaled CO concentration ( $t_{(123)}=4.24$ ,  $P<.001$  and  $t_{(134)}=5.25$ ,  $P<.001$ , respectively), and cotinine concentration ( $t_{(114)}=3.77$ ,  $P<.001$  and  $t_{(124)}=5.66$ ,  $P<.001$ , respectively). Concentrations of anatabine and anabasine did not decrease significantly at visit 4 ( $t_{(117)}=0.99$ ,  $P=.33$  and  $t_{(117)}=1.25$ ,  $P=.21$ , respectively); however, both decreased significantly at visit 5 ( $t_{(124)}=2.65$ ,  $P=.009$  and  $t_{(124)}=2.20$ ,  $P=.030$ , respectively).

The last two columns of Table 2 show the significance level for the change scores between baseline and visit 4 or visit 5 using last observation carried forward and completer analyses. Using a completer analysis, the nicotine-replacement therapy compared with placebo group showed significantly greater re-



**Table 2. Measures of Tobacco Exposure throughout the Study**

	Placebo/Nicotine Number of Participants	Placebo Mean (SD)	Nicotine Mean (SD)	<i>P</i> *	<i>P</i> †
Cigarettes per day					
Screen/baseline	94/100	8.84 (5.7)	9.99 (6.1)		
Visit 4	56/70	4.56 (5.4)	4.59 (4.7)	.16	.120
Visit 5	60/76	5.04 (6.1)	4.59 (4.9)	.077	.035
Cotinine (ng/mL)					
Screen/baseline	93/98	633 (559)	672 (438)		
Visit 4	51/64	577 (582)	542 (454)	.10	.047
Visit 5	54/72	512 (531)	492 (443)	.17	.043
Exhaled carbon monoxide (ppm)					
Baseline	94/100	8.69 (7.3)	9.43 (6.3)		
Visit 4	54/70	6.79 (6.6)	7.53 (6.0)	.99	.63
Visit 5	57/78	6.36 (6.6)	6.76 (6.2)	.70	.53
Anatabine concentration (ng/mL)					
Baseline	78/88	6.39 (10.1)	5.67 (7.2)		
Visit 4	40/46	6.38 (10.4)	5.19 (8.3)	.67	.32
Visit 5	34/50	5.18 (8.8)	3.71 (5.1)	.53	.33
Anabasine concentration (ng/mL)					
Baseline	78/90	4.73 (6.6)	4.74 (5.7)		
Visit 4	40/47	4.94 (7.1)	4.18 (6.0)	.30	.086
Visit 5	35/51	4.17 (6.6)	3.23 (4.4)	.31	.61

SD, standard deviation.

\* Substitution of missing data with the last available value (last observation carried forward) in analysis of change scores.

† Analysis of change scores for participants with follow-up data (completer analyses).

ductions in cigarettes smoked per day (−5.7 cigarettes/day [SD=6.0] compared with −3.5 cigarettes/day [SD=5.7], *P*=.035) and in cotinine concentration (−249 ng/mL [SD=397] compared with −112 ng/mL [SD=333], *P*=.04). There was also a nonsignificant trend in favor of the nicotine group on anabasine concentration at visit 4. Using the last observation carried forward analysis, none of the smoking outcomes differed significantly by treatment group, with only the number of cigarettes smoked/day showing a nonsignificant reduction with nicotine-replacement therapy.

Birth outcomes by treatment group are shown in Table 3. There were clinically important and statisti-

cally significant differences in favor of nicotine-replacement therapy in birth weight and gestational age. There were nonsignificant differences favoring nicotine-replacement therapy for neonatal length, head circumference, and Apgar score at 5 minutes. Although Apgar scores (ie, medians and 25th to 75th percentile interquartile range) were similar between groups, the full range of Apgar scores at 5 minutes was 1 to 10 for the placebo group and 5 to 10 for the nicotine group.

A nonsignificantly greater proportion of mother/newborn pairs in the placebo group experienced at least one serious adverse event (33/87 [37.9%] compared with 24/97 [24.7%] receiving nicotine-replace-

**Table 3. Birth Outcomes\***

	Placebo/Nicotine Number of Participants	Placebo Mean (SD)	Nicotine Mean (SD)	<i>P</i> †
Birth weight, g	84/93	2,950 (653)	3,287 (566)	<.001
Gestational age, wk	84/93	38.0 (3.3)	38.9 (1.7)	.014
Neonatal length, cm	80/92	49.0 (4.4)	50.0 (2.7)	.065
Head circumference, cm	72/90	33.5 (2.0)	34.0 (1.7)	.075
Apgar score‡				
1 min	84/93	8 (8, 9)	8 (8, 9)	.62
5 min		9 (9, 9)	9 (9, 9)	.061
Neonatal length of stay, d	81/91	5.46 (11.5)	3.60 (5.6)	.24§

\* Outcomes obtained on liveborn neonates.

† *t* test with nonequal variance adjustment when necessary.

‡ Median value (interquartile range) with *P* value from Mann-Whitney *U* test.

§ *P* value from square root transformation because of excessive skewness.



**Table 4. Frequency of Serious Adverse Events\***

	Placebo (n=87)	Nicotine (n=97)	P†
Maternal hospitalization	8 (9)	9 (9)	.90
Low birth weight (less than 2,500 g)	16 (18)	2 (2)	<.001
Very low birth weight (less than 1,500 g)	4 (5)	1 (1)	.19
Preterm delivery	16 (18)	7 (7.2)	.027
Range, wk			
22–27	3 (3)	0 (0)	
28–31	1 (1)	1 (1)	
32–35	4 (5)	1 (1)	
36–37	8 (9)	5 (5)	
Spontaneous abortion	0 (0)	2 (2)	.50
Intrauterine fetal demise	1 (1)	2 (2)	.54
Second trimester pregnancy loss‡	1 (1)	0 (0)	.47
Newborn death	2 (2)	1 (1)	.60
NICU admission	11 (13)	7 (7)	.20
Any SAE	33 (37.9)	24 (24.7)	.06

NICU, neonatal intensive care unit; SAE, serious adverse event. Data are n (%).

\* Excludes participants who reported elective terminations or who were lost to follow-up (ie, did not have an SAE before being lost to follow-up and who had missing perinatal outcomes).

†  $\chi^2$  test or Fisher exact test (when expected cell size is less than 5).

‡ Pregnancy loss reported at 23 weeks; medical information not available (cause unknown).

ment therapy) (Table 4). A striking difference, however, was the nine-fold incidence of newborns with low birth weight and two-fold incidence of preterm delivery in the placebo group compared with the nicotine-replacement therapy group. Although not statistically significant, the proportion of newborns with very low birth weight (less than 1,500 g) and NICU admissions, and of newborn deaths was also lower in the nicotine group. The two newborn deaths that occurred in the placebo group occurred in neonates who were born prematurely and who weighed less than 1,500 g. The newborn in the nicotine group who died was of normal birth weight, and the death occurred at 2–3 weeks of age. The autopsy report was not available, so the cause of death is unknown, but the pregnancy course was complicated by the mother's new-onset HIV infection, and the newborn death was determined by an independent obstetrician to be unrelated to study treatment. The two cases of spontaneous abortion among women in the nicotine group occurred before 12 weeks of gestation, and both women had histories of previous spontaneous abortions. The incidence of other medical conditions was comparable in the treatment groups: gestational diabetes (placebo: n=6, nicotine-replacement therapy: n=7), preeclampsia (placebo: n=3, nicotine-replace-

ment therapy: n=5), preterm premature rupture of membranes (placebo: n=4, nicotine-replacement therapy: n=6) and placental abruption (placebo: n=1, nicotine-replacement therapy: n=2). Additionally, seven participants in the placebo group and nine participants receiving nicotine-replacement therapy had evidence of other substance use at the time of delivery.

Headache, dizziness, fatigue, heartburn, nausea and vomiting were the most common nonserious adverse events (moderate or greater severity reported by at least 10% of participants) during treatment. Dizziness, heartburn, and vomiting increased significantly for both groups during treatment (McNemar change test:  $P<.001$  for dizziness and heartburn and  $P=.017$  for vomiting). The incidence of nausea increased more from baseline to treatment in the nicotine-replacement therapy group (20% compared with 40%) than in the placebo group (32% compared with 34%) (Wald  $\chi^2_{(1)}=4.47$ ,  $P=.019$ ).

Gum usage did not differ significantly by treatment group at any of the study visits, ranging from about 90% usage at visit 1 to 30% usage at visit 5. Similarly, neither the number of days of gum use (placebo: 29.9 [SD=3.4]; nicotine-replacement therapy: 37.8 [SD=3.8]) nor the average number of pieces of gum used per day (placebo: 3.22 [SD=2.27]; nicotine-replacement therapy: 3.04 [SD=2.43]) differed significantly by treatment group. There was no difference between those women who used gum and those who did not on whether they quit at visit 4 ( $\chi^2=2.16$ ,  $P=.14$ ) or visit 5 ( $\chi^2=3.18$ ,  $P=.075$ ), although there was a trend for quitters to be more likely to use gum. However, using average pieces of gum as the outcome, quitters used significantly fewer pieces of gum at visit 4 (mean [SD]=1.72 [1.41] compared with 2.86 [2.49],  $t[174]=2.09$ ,  $P=.038$ ) and visit 5 (1.61 [1.34] compared with 2.96 [2.53],  $t[174]=2.94$ ,  $P=.004$ ). A similar proportion of participants in both groups stopped gum use due to an adverse event (placebo: 14/94 [15%]; nicotine-replacement therapy: 12/100 [12%];  $\chi^2_{(1)}=.35$ ,  $P=.55$ ). The two groups could not distinguish accurately the treatment they received, with approximately one-half of participants in each group believing that they received nicotine-replacement therapy and approximately one-quarter believing that they received placebo gum ( $\chi^2_{(2)}=3.71$ ,  $P=.16$ ).

## DISCUSSION

These findings show that during pregnancy individual smoking cessation counseling with adjunctive use of 2-mg nicotine gum is associated with a modest reduc-



tion in smoking, but no increase in smoking-cessation rates. Nicotine-replacement therapy was, however, associated with a lower risk of preterm delivery and greater neonatal birth weight (ie, yielding a weight similar to that of a neonate born to a nonsmoker). There was also a trend seen for reduced neonatal length of stay and likelihood of NICU admission and higher Apgar scores at 5 minutes. If replicated, these findings have important implications for the management of smoking during pregnancy.

Our study population consisted primarily of socioeconomically disadvantaged women, including some who were being treated for mental health problems or who had a history of a substance use disorder (with some receiving methadone maintenance). These factors may have increased the external validity of the study, but may have also have lowered the observed efficacy rates. Nonetheless, our findings agree with those from a large 11-week comparison of nicotine with placebo patch in which nonsignificant differences in the rate of smoking cessation at the end of treatment (32% compared with 26%) and at the end of pregnancy (28% compared with 25%) favored the active treatment.<sup>8</sup> Our efficacy results differ from those obtained in an open-label study of adding nicotine-replacement therapy to behavioral counseling.<sup>9</sup> In that study, nicotine-replacement therapy improved overall quit rates. However, biochemically confirmed quit rates were low in both groups at the end of pregnancy (2% and 14%, for the placebo and nicotine groups, respectively).

In our study, the goal of the majority of women (85%) was to stop smoking, with the goal of the remainder being to reduce smoking as a precursor to cessation, an approach that has been used in studies in nonpregnant smokers.<sup>22</sup> We continued to provide gum to women as long as they were actively trying to quit. Our findings suggest that nicotine gum substitution may be effective for tobacco reduction during pregnancy. However, we cannot definitively conclude that nicotine gum reduced tobacco exposure since an effect on cigarettes smoked/per day and on biomarkers (ie, cotinine and anabasine) was observed only in a completer analysis, not when using a more-conservative last observation carried forward approach.

Birth weight is considered to be a directly observed biomarker that is sensitive to changes in tobacco exposure during pregnancy.<sup>23</sup> In our study, we found that birth weight was a more reliable outcome measure than other measures of tobacco exposure (as evidenced by a coefficient of variation of 17–22% for birth weight compared with 80–90% for

cotinine or other measures of tobacco exposure). Additionally, follow-up data were much more complete for birth weight than for the other biomarkers (for which 30–40% of samples were missing). As a consequence, there was greater statistical power for the analysis of birth weight as an outcome measure than for cotinine or other measures of tobacco exposure, which may explain the significant effect of nicotine-replacement therapy on birth weight but less consistent effects on the other measures.

One of the major reasons to treat pregnant smokers aggressively is to improve perinatal outcomes. The better perinatal outcomes (ie, birth weight and gestational age) with nicotine-replacement therapy in the present study may have been due to a greater reduction in smoking in that group. Another possible explanation for these findings is a beneficial effect of exogenous nicotine administration. Wisborg et al showed that the nicotine patch was associated with a birth weight that was 150 g greater than that seen with placebo treatment, despite no evidence of a greater reduction in tobacco use.<sup>8</sup> The authors suggested that nicotine could have an antiinflammatory effect by inhibiting the production of thromboxane, which may increase birth weight by reducing placental vasoconstriction and platelet aggregation. The better outcomes in the nicotine group could also have been mediated by greater treatment retention in that group, which could reflect greater compliance overall with prenatal care and could yield better birth outcomes.

Irrespective of the mechanism, the decreased risk of low birth weight and preterm delivery associated with nicotine-replacement therapy is clinically important. Two of the very low birth weight neonates in the placebo group died shortly after delivery. Other low birth weight neonates who survived had NICU stays of up to 3 months. These neonates are at high risk of long-term morbidity.<sup>24,25</sup> Moreover, the cost of treating these low birth weight neonates is approximately 1 million dollars. With the prevalence of smoking in pregnant women being 12%, a modest reduction in the risk of low birth weight and premature delivery can, in the aggregate, be very great.

Although we examined the effect of nicotine gum on both smoking cessation and reduction, we do not recommend that nicotine gum be used routinely in prenatal care to promote smoking reduction. Cotinine monitoring was necessary to ensure that nicotine exposure was not increased above that resulting from smoking. In animal studies, nicotine causes abnormalities of cell proliferation and differentiation, leading to a reduced number of neurons and eventually to



altered synaptic activity, suggesting a link to sudden infant death syndrome.<sup>26</sup>

In summary, this study suggests that 2-mg nicotine gum does not increase smoking-cessation rates but may reduce overall tobacco exposure during pregnancy. Nicotine gum was associated with greater birth weight and gestational age than placebo gum, yielding parameters similar to those of a nonsmoker.

## REFERENCES

1. Hoffmann D, Hoffmann I. The changing cigarette. *J Toxicol Environ Health* 1997;50:307-64.
2. Ventura SJ, Hamilton BE, Mathews TJ, Chandra A. Trends and variations in smoking during pregnancy and low birth weight: evidence from the birth certificate, 1990-2000. *Pediatrics* 2003;111:1176-80.
3. Women and smoking: a report of the surgeon general. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2001.
4. Hoyert DL, Mathews TJ, Menacker F, Strobino DM, Guyer B. Annual summary of vital statistics: 2004 [published erratum appears in *Pediatrics* 2006;117:2338]. *Pediatrics* 2006;117:168-83.
5. DiClemente CC, Dolan-Mullen P, Windsor RA. The process of pregnancy smoking cessation: implications for interventions. *Tob Control* 2000;9:16-21.
6. Fingerhut LA, Kleinman JC, Kendrick JS. Smoking before, during, and after pregnancy. *Am J Public Health* 1990;80:541-4.
7. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating tobacco use and dependence. A clinical practice guideline. Washington (DC): U.S. Department of Health and Human Services, Public Health Services; 2000. Available at [www.surgeongeneral.gov/tobacco/treating\\_tobacco\\_use.pdf](http://www.surgeongeneral.gov/tobacco/treating_tobacco_use.pdf). Retrieved December 16, 2007.
8. Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine patches for pregnant smokers: a randomized controlled study. *Obstet Gynecol* 2000;96:967-71.
9. Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK, et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. *Am J Prev Med* 2007;33:297-305.
10. Oncken CA, Hatsukami DK, Lupo VR, Lando HA, Gibeau LM, Hansen RJ. Effects of short-term nicotine gum use in pregnant smokers. *Clin Pharmacol Ther* 1996;59:654-61.
11. Jacob P, Hatsukami D, Severson H, Hall S, Yu L, Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. *Cancer Epidemiol Biomarkers Prev* 2002;11:1668-73.
12. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition with psychotic screen (SCID-I/P W/PSY SCREEN). New York (NY): Biometrics Research, New York State Psychiatric Institute; 2002.
13. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict* 1991;86:1119-27.
14. Fava JL, Ruggiero L, Grimley DM. The development and structural confirmation of the Rhode Island Stress and Coping Inventory. *J Behav Med* 1998;21:601-11.
15. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med* 1994;10:77-84.
16. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. *J Stud Alcohol Suppl* 1994; 70-5.
17. Rollnick S, Butler CC, Stott N. Helping smokers make decisions: the enhancement of brief intervention for general medical practice. *Patient Educ Counsel* 1997;31:191-203.
18. Rollnick S, Heather N, Bell A. Negotiating behaviour change in medical settings: the development of brief motivational interviewing. *J Mental Health* 1992;1:25-37.
19. Dornelas EA, Magnavita J, Beazoglou T, Fischer EH, Oncken C, Lando H. Efficacy and cost-effectiveness of a clinic-based counseling intervention tested in an ethnically diverse sample of pregnant smokers. *Patient Educ Couns* 2006;64:342-9.
20. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: Toward an integrative model of change. *J Consult Clin Psychol* 1983;51:390-5.
21. Hatsukami DK, Hughes JR, Pickens RW, Svikis D. Tobacco withdrawal symptoms: an experimental analyses. *Psychopharmacology (Berl)* 1984;84:231-6.
22. Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. *The Cochrane Database of Systematic Reviews* 2007, Issue 3. Art No.: CD005231. DOI: 10.1002/14651858.CD005231.pub2.
23. Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. *Nicotine Tob Res* 2006;8:169-91.
24. Barker DJ, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. *Int J Epidemiol* 2002;31:1235-9.
25. Nomura Y, Brooks-Gunn J, Davey C, Ham J, Fifer WP. The role of perinatal problems in risk of co-morbid psychiatric and medical disorders in adulthood. *Psychol Med* 2007;37:1323-34.
26. Slotkin TA. Fetal nicotine or cocaine exposure: Which one is worse? *J Pharmacol Exp Ther* 1998;285:931-45.

